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ABSTRACT
Objectives: Cisplatin is a classical anticancer drug used in the treatment of ovarian cancer. Unfortunately, the treatment 
is associated with numerous adverse effects. Studies concerning new platinum derivatives with less organ toxicity are 
conducted. The aim of this study was to analyse the effect of a new trans-platinum(II) complex of 3-aminoflavone on the 
viability and mortality of the cells from OVCAR 3 and CAOV 3 ovarian cancer cell lines and on the expression of the selected 
genes involved in the process of apoptosis. 
Material and methods: The viability of ovarian cancer cells and the cytotoxicity of a trans-platinum(II) complex of 3-amino-
flavone: [trans-Pt(3-af )2Cl2), trans-bis-(3-aminoflavone) dichloridoplatinum(II)] and cisplatin were analysed using a spectro-
photometric method with the use of MTT assay and LDH assay. BAX, BCL2, BIRC5 gene expression analysis on mRNA level 
was conducted with the use of Real-Time PCR method.
Results: It was observed that parallel to an increase in the concentration of the new complex compound and cisplatin 
there is a decrease in viability and an increase in mortality of ovarian cancer cells. As a result of exposure to the studied 
compound and cisplatin, an increased BAX gene expression and decreased BCL2 and BIRC5 gene expression were observed 
in the studied ovarian cancer cell lines.
Conclusion: Trans-Pt(3-af )2Cl2 exhibits anticancer activity towards OVCAR 3 and CAOV 3 ovarian cancer cell lines. The 
studied complex compound can be considered as a potential anticancer drug. 
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INTRODUCTION
In 1965 the publication in Nature of the results of 
a study directed by Rosenberg opened new perspectives 
of cisplatin (cis — diamminedichloridoplatinum(II), CDDP) 
use in anticancer treatment [1]. In that study a chemothera-
peutic potential of cisplatin was described. Rosenberg et al. 
investigated how microorganisms (E. coli bacteria) behave 
under the influence of electric current. Thus the scientists 
proved that platinum electrodes used during the studies 
caused the death of cancer cells. Its mechanism of action 
relies on binding to DNA via N7 guanine and adenosine 
atoms [2, 3]. The 1.2 intrastrand crosslinks are responsible 
for the activity of platinum complexes. Cisplatin is widely 
used in the anticancer therapy against many neoplasms, 
especially ovarian cancer, testicular cancer, head and neck 
cancer and lung cancer [4, 5]. It should be noted that be-
sides the common use of cisplatin many patients develop 
resistance to this drug and numerous side effects occur, 
such as organ toxicity e.g. nephrotoxicity, reduction in 
the number of bone marrow cells and increased risk of 
deep vein thrombosis [6, 7]. Therefore, new platinum de-
rivatives and complexes are being searched for. There are 
numerous studies concerning characterising platinum in 
trans configuration [8]. Transplatin forms 1.3 intrastrand 
bonds, crosslinks, equivalent to cisplatin, interstrand 
and monofunctional links. Trans isomer does not show 
any anticancer activity [9, 10]. During recent years some 
reports have appeared, indicating that in a transplatin 
molecule a substitution of amine group with a suitable 
ligand increases the anticancer activity of the compound 
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[11–13]. A potential synergistic effect between flavonoids 
and metal ions as well as some properties of trans-platinum 
complexes have encouraged also our team to synthesize 
a new platinum(II) compound with flavonoid ligand and to 
investigate its anticancer activity. Our studies revealed that 
the new trans-Pt(3-af )2Cl2 compound exhibits a significant 
cytotoxic activity towards the cells from the selected can-
cer cell lines, IC50 within the rage of 4.6–16.3 μM [11]. The 
studied compound was only slightly less active towards 
neoplastic cells compared to cisplatin. What is more, it 
was also less toxic towards human lymphocytes than cis-
platin, that is a highly demanded feature when taking into 
consideration the prevention of potential side effects of 
chemotherapy. The studied compound did not show any 
differences in activity towards the sensitive lines (L1210 and 
EJ) and the sublines resistant to cisplatin (L1210R and EJ-
cisR) [11]. What is interesting, despite lesser cytotoxicity, 
the studied compound was a stronger inducer of apoptosis 
than cisplatin [11]. The present paper aims at characteris-
ing the antineoplastic activity of a new trans-platinum(II) 
complex of 3-aminoflavone towards ovarian cancer cells. 
Ovarian cancer is the main cause of death in oncological 
gynaecology both in Poland and worldwide, what is con-
firmed by epidemiological data [14, 15]. In 2010 in Poland 
ovarian cancer was diagnosed in 3.587 women and was the 
cause of death of 2.547 people [15]. In 2012 approximately 
239.000 of new cases of ovarian cancer and 152.000 of 
deaths caused by ovarian cancer were registered worldwide 
[14]. In one of the hypotheses concerning ovarian cancer, 
Spencer Wells claimed that in a single layer of epithelium 
covering the ovary, as a result of different stimulating factors, 
a cancerogenesis process is initiated and it leads to cancer 
development [16]. 
Ovarian cancer is a malignant cancer showing high het-
erogeneity with regard to its origin, histological structure, 
disease course and methods of treatment. It is a cancer 
of epithelial origin and its ability to disseminate into the 
peritoneal cavity is a feature used to distinguish this car-
cinoma from others. In advanced stages of the disease the 
peritoneal cavity is the main place where metastases are 
formed, and it is especially observed in stage 3 and 4 [17, 18]. 
When infiltrating the peritoneal cavity cancer cells undergo 
epithelial-mesenchymal transition (EMT) resulting in the loss 
of cadherin-E-dependent intercellular interactions. Conse-
quently, they start to detach from the surface of the primary 
tumour. Cancer cells are detached from the primary tumour 
and captured by the peritoneal fluid. CD44 glycoprotein 
participates in the migration of ovarian cancer cells. There-
fore, ovarian cancer cells may be from the tumour or as-
cites. Therefore, an important element of studies was to 
compare the effects of a new compound on two cell lines 
presenting various background with regard to the origin of 
ovarian cancer cells. A prognosis is also an important aspect 
— when the carcinoma is diagnosed late chances of cure 
are lower, as cancer cells become more invasive, aggressive 
and resistant to chemotherapy (OVCAR 3). 
CA125 and CD44 integrins participate in the mechanism 
of metastasis formation.
In 1998 Dubean questioned the fact that all the ovar-
ian neoplasms are derived from the epithelium covering 
the ovary [19]. Despite the progress in medicine and in the 
methods of molecular biology there is still lack of a clear 
hypothesis on the development of ovarian cancer [20]. 
Ovarian cancer is a serious diagnostic and therapeutic 
problem in the contemporary medicine. One of significant 
difficulties during the therapeutic process is the occurrence 
of resistance to cytotoxic treatment. In ovarian cancer chemo-
therapy based on several treatment regimens is applied and 
the chemotherapeutic agents used include: cisplatin, carbopl-
atin, paclitaxel, etoposide, topotecan [21, 22]. The studies have 
shown some disturbances during the course of apoptosis in 
ovarian cancer cells [23, 24]. Cancer cells are characterised 
by the resistance to apoptosis [23]. Apoptosis is a complex 
process, which constitutes a programmed cell death. Both 
inhibition and excessive occurrence of apoptosis can become 
a cause of many diseases. Many proteins and genes, i.e.: BAX, 
BCL2, BIRC5 are involved in the regulation of the process of 
apoptosis. BAX is one of the proapoptotic genes, inducing 
the apoptosis [25]. BCL2 inhibits the process of apoptosis [26]. 
BIRC5 belongs to the inhibitors of apoptosis [27].
OBJECTIVES
The aim of the present paper was to analyse the influ-
ence of trans-platinum(II) complex of 3-aminoflavone on 
the viability and mortality of the cells from OVCAR 3 and 
CAOV 3 ovarian cancer cell lines as well as the expression 
of the selected genes involved in the process of apoptosis. 
MATERIAL AND METHODS 
Cell culture
The studies were performed on two ovarian cancer cell 
lines: OVCAR 3 (ATCC HTB-161) and CAOV 3 (ATCC HTB-75)
purchased at the American Type Culture Collection (ATCC) 
bank in the USA.
CAOV 3 is an ovarian cancer cell line with epithelial 
morphology. This line was established from the primary 
tumour of a 54-year-old female with adenocarcinoma of 
the ovary. Cancer cells are sensitive to vinblastine, cisplatin 
and adriamycin [28].
OVCAR 3 was established in 1982 by Hamilton et al. from 
malignant ascites of a female with progressive adenocarci-
noma of the ovary. It is a cell model to study resistance to 
medicinal products used in the treatment of ovarian cancer. 
This line is resistant to cisplatin, adriamycin and melphalan. 
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Thanks to these properties it is very good material for stud-
ies on new formulas, medications and compounds. OVCAR 
3 includes cancer cells that are highly aggressive.The cells: 
OVCAR 3 and CAOV 3 show expression of CA125 [28, 29].
OVCAR 3 and CAOV3 are both used as a cell model to 
study cisplatin [30, 31]. 
Cell cultures were maintained in standard conditions in 
Panasonic incubator (temperature: 37°C, humidity: 5% CO2); 
sterile Nunc cell culture vessels were used. The DMEM culture 
medium + GlutaMAX (Thermo Fisher Scientific, USA) was 
used for CAOV3 cell cultures, whereas for the OVCAR3 cells 
growth, the RPMI Medium 1640 (Thermo Fisher Scientific, 
USA) together with insulin Gensulin N (Bioton, Poland) was 
applied. Culture media were enriched with 10% fetal bovine 
serum (FBS, Lonza, USA) and AAS antibiotics (penicillin, 
streptomycin, amphotericin B, Sigma-Aldrich, USA). Cisplatin 
(Sigma-Aldrich, USA) and trans-Pt(3-af )2Cl2 synthesized in 
the Department of Bioinorganic Chemistry of the Medical 
University of Łódź were used in the study. The compound 
was synthesized as described in the publication [11]. Both 
cisplatin and the studied compound were dissolved in 
DMF(Sigma-Aldrich, USA) to the determined concentrations.
The MTT assay — a spectrophotometric 
determination of the viability of ovarian cancer 
cells after treatment with a trans-platinum(II) 
complex of 3-aminoflavone and cisplatin
The MTT assay relies on a colorimetric determination 
of a coloured product - formazan forming as a result of 
metabolizing of MTT,  3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide, (Sigma-Aldrich, USA) by cel-
lular enzymes. The cells were seeded in a 24-well plate in 
the number of 20 x 103/well in 500 µl of DMEM and RPMI 
culture media. In the experiment the cells were incubated for 
72 hours in the fresh culture media with increasing concen-
trations, from 5 to 100 µM, of trans-Pt(3-af )2Cl2 and cisplatin. 
After the 72-hour culture of cells with chemotherapeutic 
agents, the culture media were removed and 500 µl of MTT 
reagent (5 mg/mL) were added to each well; then the plate 
was left for incubation at 37ºC. After three hours, isopropa-
nol (POCH, Poland) was added to the wells containing the 
cells in order to dissolve formazan crystals. The absorbance 
was measured at 540 and 690 nm using Epoch Microplate 
Spectrophotometer (Bio Tek, USA). All the experiments were 
repeated 3 times for each concentration; the arithmetic 
mean was considered as the final result.
The LDH assay — a determination of cell death 
Cytotoxicity of the studied compounds was determined 
with the use of CytoSelect™ LDH Cytotoxicity Assay Kit (Cell 
Biolabs, USA) investigating the activity of a cytoplasmic 
enzyme — lactate dehydrogenase. The cells were seeded in 
24-well dishes with a density of 20 × 103 cells/well in 500 µl 
of DMEM and RPMI medium. After the 72-hour incubation of 
the cells with cytostatic agents (IC50: for CAOV3 line: cisplatin 
and trans-Pt(3-af )2Cl2 — 10 µM; OVCAR3 line: cisplatin and 
trans-Pt(3-af )2Cl2 — 50 µM) 90 µl of the culture medium 
were transferred on a 96-well plate and 10 µl of a reagent 
for the reaction catalysed by LDH were added. The plate 
was incubated for 3 hours at 37ºC. After the incubation the 
coloured product of the reaction was measured using BioTek 
plate reader at the wavelength of 450 nm. 
RNA isolation and reverse transcription reaction 
Ovarian cancer cells from the OVCAR 3 and CAOV3 lines 
were exposed to the effects of cisplatin and study compound 
at IC50 levels. The RNA isolation from the ovarian cancer cells 
was conducted according to the method of Chomczyński 
and Sacchi, with the use of TRIzol reagent (Thermo Fisher 
Scientific, USA). The purity of the obtained RNA was assessed 
by spectrophotometric method on Q 5000 Quawell UV-Vis 
spectrophotometer, measuring the absorbance at the wave-
length of 260 nm and 280 nm. The A260/A280 value within 
the range of 1.8–2.0 was the RNA purity criterion. The reverse 
transcription reaction was conducted with the use of High 
Capacity RNA-to-cDNA Kit (Thermo Fisher Scientific, USA) 
according to the manufacturer’s protocol. After that cDNA 
was frozen and kept at –20°C for further analyses. 
Real-Time PCR reaction
The following TaqMan probes were used in the Real-Time 
PCR reaction: BAX — Hs00180269_mL, ACTB - Hs01060665_
gL, BCL2 Hs 00608023-mL, BIRC5 Hs 00153353-mL (Thermo 
Fisher Scientific, USA). In the Real-Time PCR reaction, the 
obtained cDNA molecules constituted a matrix for the deter-
mination of BAX, BCL2, BIRC5 gene expression. The reaction 
mixture constituted of: 0.5µl of TaqMan Gene Expression As-
say probe (Thermo Fisher Scientific, USA), 5 µl of TaqMan Gene 
Expression Master Mix (Thermo Fisher Scientific, USA), 2.5 µl of 
water and 50 ng of cDNA per well. The Real-Time PCR reaction 
was conducted in ViiA7 instrument (Thermo Fisher Scientific, 
USA). The obtained gene expression results were compared 
with the reference gene ACTB. Relative gene expression level 
was calculated with the use of 2– ΔΔCT method. 
Statistical analysis
The statistical analysis was conducted using Graph-
PAD Prism 6 computer program by GraphPad Software Inc. 
The results of the experiments were analysed by Bonfer-
roni test in order to determine the statistically significant 
differences between the control groups and the studied 
compounds. The differences were considered statistically 
significant at the confidence level below 0.05 (* p < 0.05; ** 
p < 0.01; *** p < 0.001, ****p < 0.0001).
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RESULTS
The viability assessment of ovarian cancer 
cells of ascites and tumour cell lines after the 
exposure to the trans-platinum(II) complex of 
3-aminoflavone and cisplatin
The MTT assay was applied in order to assess the in-
fluence of the studied compound and cisplatin on ovar-
ian cancer cells from OVCAR 3 and CAOV 3. The studies 
have demonstrated that together with the increase in the 
concentrations within the range of 5-100 µM, there is a de-
crease in viability of the CAOV 3 (Fig. 1) and OVCAR 3 (Fig. 2) 
cancer cell lines. Some experiments on reference com-
pounds (3-aminoflavone, transplatin) were also carried out. 
The results of the MTT assay are shown in Figure 3.
The cytotoxicity assessment of the studied compounds 
by the LDH method (Fig. 4).
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Figure 1. The viability of the cells from CAOV 3 ovarian cancer cell line after the 72-hour incubation with cisplatin and trans-Pt(3-af )2Cl2. Three 
independent experiments in three repeats were performed. The mean values marked as * (p < 0.05), **** (p < 0.0001) are statistically significantly 
different from controls
150
100
50
0
Su
rv
iv
al
 (%
)
k 5 10 25 50 75 100
**
* ** **
*
Cisplatin [μM]
150
100
50
0
Su
rv
iv
al
 (%
)
k 5 10 25 50 75 100
*
** ** **
trans-Pt(3 – af)2Cl2 [μM]
Figure 2. The viability of the cells from OVCAR 3 ovarian cancer cell line after the 72-hour incubation with cisplatin and trans-Pt(3-af )2Cl2. Three 
independent experiments in three repeats were performed. The mean values marked as * (p < 0.05), ** (p < 0.01) are statistically significantly 
different from controls
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Figure 3. The MTT assay results determining the anticancer activity 
of 3-aminoflavone and transplatin in CAOV 3 and OVCAR 3 cell lines 
after the 72-hour incubation
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The effect of trans-Pt(3-af)2Cl2 and cisplatin  
on BAX, BCL2, BIRC5 gene expression
BAX, BCL2, BIRC5 gene expression on the mRNA level was 
analysed in the cells from OVCAR 3 and CAOV 3 ovarian cancer 
cell lines after the exposure to trans-Pt(3-af)2Cl2 and cisplatin in 
the concentration of IC50, during 72 hours. Cells that were not 
treated with the studied compounds served as controls. The 
studies have shown an increase in BAX gene expression, and 
a decrease in BCL2 and BIRC5 gene expression (Fig. 5–7).
DISCUSSION 
A combination of chemotherapy based on platinum 
derivatives is routinely used in patients after cytoreductive 
surgery, but only approximately 70–80% of patients with 
ovarian cancer respond positively to chemotherapy [32].
Moreover, drug resistance that occurs in patients de-
creases cell sensitivity to chemotherapy, causes disease 
recurrence and contributes to metastasis formation. These 
result in a worse prognosis. Therefore, it is very important 
to get to know the mechanisms that determine drug resist-
ance. However, it is cisplatin that, despite the numerous side 
effects, is the most often used chemotherapeutic agent [33]. 
Ineffective apoptosis can be the cause of chemoresistance 
of cancer cells [34].
In the search for new drugs, in recent years there has been 
a significant interest in trans-platinum compounds. Transplatin 
is less toxic for tumour cells than cisplatin [35]. The cytotoxic-
ity of trans-platinum complexes with ligands is higher [11].
The platinum(II) compound with 3-aminoflavone was 
synthesized in the Department of Bioinorganic Chemistry 
of the Medical University of Łódź. The results of the studies 
presented in this paper indicate that the new compound 
exhibits anticancer properties against ovarian cancer cells. In 
the studies molecular biology methods were applied — the 
in vitro assessment of the proapoptotic activity of the stud-
ied compound. In ovarian cancer disturbances in the process 
Figure 4. The cytotoxic effect of the studied compound and cisplatin on the cells from OVCAR 3 and CAOV 3 cell 
lines assessed using the LDH assay. The mean values marked as * (p < 0.05) are statistically significantly different from 
controls
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Figure 5. BAX gene expression in OVCAR 3 and CAOV 3 ovarian cancer cells treated with cisplatin and trans-Pt(3-af )2 Cl2. The gene expression 
level was expressed as relative values compared to the control that equals 1. The mean values marked as ** (p < 0.01) are statistically significantly 
different from controls
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of apoptosis are observed. That is why our aim was to analyse 
the effect of both cisplatin and the compound on the expres-
sion of key genes associated with apoptosis. 
In the present paper it was demonstrated that both 
cisplatin and the studied compound with increasing dose 
values decrease the viability of ovarian cancer cells. The 
obtained results concerning cisplatin are consistent with 
the available data in the literature [36, 37]. Smith et al. 
treated CAOV 3 and OVCAR 3 ovarian cancer cells with cis-
platin and demonstrated the decrease in cell viability [36]. 
Thomadaki et al. also showed that after the administration 
of cisplatin to the cells, a decrease in viability occurs [37]. In 
the presented study the analysis of cisplatin effect on the 
expression of genes involved in the process of apoptosis 
showed that the studied drug causes an increase in BAX 
gene expression.
The studies demonstrated that after the exposure to cis-
platin, the BCL2 gene activity is characterised by a decrease 
in the expression compared to the non-treated ovarian can-
cer cells. Ding et al. treated the cells from SKOV 3 ovar-
ian cancer cell line with cisplatin and showed a decrease in 
BCL2 gene expression [38]. The studied newly-synthesized 
compound trans-Pt(II) with 3-aminoflavone showed, simi-
larly to cisplatin, an increase in BAX gene expression. Identi-
cal result was obtained when cis-Pt(II) with 3-aminoflavone 
was studied [39]. The compound causes a decrease in the 
expression of BCL antiapoptotic gene. In the present paper 
it is also indicated that after the exposure of ovarian cancer 
cells to the studied compound and cisplatin, a decrease in 
the survivin gene expression occurs. Lesan et al. investigated 
the effect of metformin and cisplatin on gastric cancer cells 
and have also demonstrated a decrease in the survivin gene 
expression in cells [40]. Moreover, Wang et al. also showed 
that after the treatment of ovarian cancer cells with cisplatin, 
a decrease in the survivin gene expression occurs [41]. The 
conducted analyses are the first studies on the effect of the 
new platinum(II) compound on ovarian cancer cell lines. The 
results of our studies indicate that trans-Pt(3-af )2Cl2 exhibits 
anticancer properties on the level comparable to cisplatin 
— a classical drug, routinely used in clinical departments. 
CONCLUSIONS
A trans-platinum(II) complex of 3-aminoflavone decreas-
es the viability of ovarian cancer cells in the doses compa-
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Figure 6. BCL2 gene expression in OVCAR 3 and CAOV 3 ovarian cancer cells treated with cisplatin and trans-Pt(3-af )2 Cl2. The gene expression 
level was expressed as relative values compared to the control that equals 1. The mean values marked as * (p < 0.05) are statistically significantly 
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Figure 7. BIRC5 gene expression in OVCAR 3 and CAOV 3 ovarian cancer cells treated with cisplatin and trans-Pt(3-af )2 Cl2. The gene expression 
level was expressed as relative values compared to the control that equals 1
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rable to cisplatin. It was demonstrated that this compound 
induces the expression of proapoptotic gene BAX.
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